Business Context and Reporting Period
This Form 8-K Current Report was filed by InMed Pharmaceuticals Inc. on March 18, 2022, covering events occurring on March 17, 2022. The Company is a British Columbia corporation with its principal executive offices in Vancouver, Canada, and its common shares trade on The Nasdaq Stock Market LLC under the symbol "INM". The filing primarily addresses executive leadership changes within the finance department.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to the compensation arrangement for the new Interim Chief Financial Officer, Ms. Brenda Edwards, who is engaged through a placement agent at an hourly rate of CAD$210.
Material Changes
- Departure of CFO: Mr. Bruce Colwill is retiring as Chief Financial Officer, effective March 31, 2022. He will serve as an advisor until June 30, 2022, to ensure a smooth transition.
- Appointment of Interim CFO: Ms. Brenda Edwards was appointed Interim Chief Financial Officer, effective April 1, 2022.
- Search for Permanent Replacement: The Company has initiated a search for a full-time permanent Chief Financial Officer.
Management Commentary and Risks
Management highlighted Ms. Edwards' extensive background, including over 35 years of experience and more than 20 years as a CFO for private and public companies. Her expertise covers mergers and acquisitions, financings, high-growth management, and financial reporting. She is a member of the American Institute of CPAs and the Chartered Professional Accountants of Canada. The filing notes that the press release regarding these changes is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the exact effective dates for Mr. Colwill's retirement (March 31, 2022) and Ms. Edwards' appointment (April 1, 2022).
- Confirm the hourly compensation rate of CAD$210 for the Interim CFO services.
- Monitor future filings for the announcement of a permanent Chief Financial Officer.
- Review the press release (Exhibit 99.1) for any additional details on the transition plan not included in the 8-K text.